Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-23-073324
Filing Date
2023-06-21
Accepted
2023-06-21 16:05:35
Documents
2
Period of Report
2023-06-19

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2319343d1_3.html 3  
1 OWNERSHIP DOCUMENT tm2319343d1_3.xml 3 1593
2 EXHIBIT 24 tm2319343d1_ex24.htm EX-24 4175
  Complete submission text file 0001104659-23-073324.txt   7533
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Issuer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address BRAINSTORM CELL THERAPEUTICS, INC. 1325 AVENUE OF AMERICAS, 28TH FLOOR NEW YORK NY 10019
Business Address
Naor Nir (Reporting) CIK: 0001982278 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36641 | Film No.: 231029844